12/06/2026 20:17
|
Medical, Health & Aged Care
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment
BRUKINSA plus...